PDCD1 and renal cell carcinoma: The most common underlying malignancy among patients treated with PD-L1 inhibitors was NSCLC (94.4%), whereas the most prevalent malignancy for patients treated with PD-1 inhibitors was melanoma (34.5%), followed by, NSCLC (30.1%) and renal cell carcinoma (14.3%).